ALLSCHWIL and BASEL, Switzerland, Jan. 21, 2008 (PRIME NEWSWIRE) -- Actelion Ltd (VTX:ATLN) (Other OTC:ALIOF) today announced un-audited 2007 total net revenues of CHF 1'317.4 million (FY 2006: CHF 945.7 m). This performance is the result of strong product sales, driven by Tracleer(r). In 2007, Actelion's lead product for the treatment of Pulmonary Arterial Hypertension achieved total sales of CHF 1'178.6 million (FY 2006: 898.7 m), with continuous growth recorded in all territories worldwide.
On 21 February 2008, Actelion will report fully audited 2007 financial results. The company expects to report Cash EBIT slightly above the previous guidance range of CHF 430 to 460 million.
For documentation purposes - table FY 2007 vs. FY 2006
In CHF thousands Results FY 2007 Results FY 2006 Variance in % Net Revenues 1'317.4 945.7 371.7 39 - Tracleer 1'178.6 898.7 279.9 31 - Ventavis 78.2 na na na - Zavesca 35.3 25.5 9.9 39 - Contract revenues 25.3 21.5 3.8 18
For documentation purposes - table Q3 2007 vs. Q4 2007
In CHF thousands Results Q4 2007 Results Q3 2007 Variance in % Net Revenues 370.9 320.1 50.8 16 - Tracleer 332.0 286.6 45.4 16 - Ventavis 23.4 18.9 4.5 24 - Zavesca 9.4 9.0 0.4 5 - Contract revenues 6.1 5.6 0.5 8
A proportion of the quarterly increases or decreases in Tracleer(r) and Ventavis(r) sales might be attributable to buying pattern variations.
Corporate Calendar 2008
21 Feb Full Year Results 2007
(Media & Analyst Day in Zurich, Unique Airport
Conference Center)
11 Apr AGM 2008 in Basel
22 Apr Quarter 1 Results 2008
22 Jul Half-Year Results 2008
H2 Actelion R&D Day
21 Oct 9-months Results 2008
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(r), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(r) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. At the end of September 2006, Tracleer(r) was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (VTX:ATLN) (Other OTC:ALIOF).